These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35661725)

  • 1. Controversy of Preoperative Exposure to Tumor Necrosis Factor Inhibitors in Surgical and Infectious Complications of Inflammatory Bowel Disease.
    Zhu Z; Gao Z; Li K
    Gastroenterology; 2023 Feb; 164(2):307-308. PubMed ID: 35661725
    [No Abstract]   [Full Text] [Related]  

  • 2. Prospective Cohort Study to Investigate the Safety of Preoperative Tumor Necrosis Factor Inhibitor Exposure in Patients With Inflammatory Bowel Disease Undergoing Intra-abdominal Surgery.
    Cohen BL; Fleshner P; Kane SV; Herfarth HH; Palekar N; Farraye FA; Leighton JA; Katz JA; Cohen RD; Gerich ME; Cross RK; Higgins PDR; Tinsley A; Glover S; Siegel CA; Bohl JL; Iskandar H; Ji J; Hu L; Sands BE
    Gastroenterology; 2022 Jul; 163(1):204-221. PubMed ID: 35413359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic Review and Meta-Analysis: Preoperative Vedolizumab and Postoperative Complications in Patients with IBD.
    Moosvi Z; Duong JT; Bechtold ML; Nguyen DL
    South Med J; 2021 Feb; 114(2):98-105. PubMed ID: 33537791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis.
    Billioud V; Ford AC; Tedesco ED; Colombel JF; Roblin X; Peyrin-Biroulet L
    J Crohns Colitis; 2013 Dec; 7(11):853-67. PubMed ID: 23523418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review and meta-analysis: risks of postoperative complications with preoperative use of anti-tumor necrosis factor-alpha biologics in inflammatory bowel disease patients.
    Moosvi Z; Duong J; Bechtold ML; Nguyen DL
    Eur J Gastroenterol Hepatol; 2021 Jun; 33(6):799-816. PubMed ID: 33079779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Postoperative Infectious Complications From Medical Therapies in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    Law CCY; Koh D; Bao Y; Jairath V; Narula N
    Inflamm Bowel Dis; 2020 Nov; 26(12):1796-1807. PubMed ID: 32047894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience.
    Rizzo G; Armuzzi A; Pugliese D; Verbo A; Papa A; Mattana C; Rapaccini GL; Guidi L; Coco C
    Int J Colorectal Dis; 2011 Nov; 26(11):1435-44. PubMed ID: 21594668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low Serum Tumor Necrosis Factor-α Antagonist Concentrations in Patients With Inflammatory Bowel Disease Who Achieve Healing From Pyoderma Gangrenosum.
    Mikail M; Wilson A
    Inflamm Bowel Dis; 2021 Oct; 27(11):e141-e143. PubMed ID: 34089257
    [No Abstract]   [Full Text] [Related]  

  • 9. A More Severe Non-melanoma Skin Cancer Phenotype Is Seen in Patients with Inflammatory Bowel Disease on Tumor Necrosis Factor-α Antagonists.
    Townsend CM; Khanna R; Wilson AS
    Dig Dis Sci; 2021 Dec; 66(12):4436-4440. PubMed ID: 33428042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-Tumor Necrosis Factor-α Antibody Therapy Management Before and After Intestinal Surgery for Inflammatory Bowel Disease: A CCFA Position Paper.
    Holubar SD; Holder-Murray J; Flasar M; Lazarev M
    Inflamm Bowel Dis; 2015 Nov; 21(11):2658-72. PubMed ID: 26422516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of Biological Therapy Before Elective Inflammatory Bowel Disease Surgeries.
    Hansen TM; Targownik LE; Karimuddin A; Leung Y
    Inflamm Bowel Dis; 2019 Sep; 25(10):1613-1620. PubMed ID: 30794289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histopathologic study of paradoxical psoriasis induced by antitumor necrosis factor alpha therapy: Is it true psoriasis?
    Navarro R; Villar-Zarra K; Juarez Á; Daudén E
    J Cutan Pathol; 2021 Jun; 48(6):813-816. PubMed ID: 33205481
    [No Abstract]   [Full Text] [Related]  

  • 13. Incidence Rates of Psoriasis in Children With Inflammatory Bowel Disease and Juvenile Arthritis Treated With Tumor Necrosis Factor Inhibitors and Disease-Modifying Antirheumatic Drugs.
    Baggett K; Brandon TG; Xiao R; Valenzuela Z; Buckley LH; Weiss PF
    J Rheumatol; 2022 Aug; 49(8):935-941. PubMed ID: 35428721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Preoperative Nutritional Status on the Incidence Rate of Surgical Complications in Patients With Inflammatory Bowel Disease With Vs Without Preoperative Biologic Therapy: A Case-Control Study.
    Yamamoto T; Shimoyama T; Umegae S; Kotze PG
    Clin Transl Gastroenterol; 2019 Jun; 10(6):e00050. PubMed ID: 31136361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the Cause of Weight Gain in Patients With IBD on Anti-TNF Medications.
    Winter RW; Friedman S
    Inflamm Bowel Dis; 2020 Jan; 26(1):132-133. PubMed ID: 31265724
    [No Abstract]   [Full Text] [Related]  

  • 16. Pulmonary Manifestations of Inflammatory Bowel Disease.
    Massart A; Hunt DP
    Am J Med; 2020 Jan; 133(1):39-43. PubMed ID: 31398306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No effect of anti-TNF-α agents on the surgical stress response in patients with inflammatory bowel disease undergoing bowel resections: a prospective multi-center pilot study.
    El-Hussuna A; Qvist N; Zangenberg MS; Langkilde A; Siersma V; Hjort S; Gögenur I
    BMC Surg; 2018 Nov; 18(1):91. PubMed ID: 30390672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between vedolizumab and postoperative complications in IBD: a systematic review and meta-analysis.
    Guo D; Jiang K; Hong J; Zhang M; Shi Y; Zhou B
    Int J Colorectal Dis; 2021 Oct; 36(10):2081-2092. PubMed ID: 34467414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively With Vedolizumab.
    Yamada A; Komaki Y; Patel N; Komaki F; Aelvoet AS; Tran AL; Pekow J; Dalal S; Cohen RD; Cannon L; Umanskiy K; Smith R; Hurst R; Hyman N; Rubin DT; Sakuraba A
    Am J Gastroenterol; 2017 Sep; 112(9):1423-1429. PubMed ID: 28719595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative biological therapy and short-term outcomes of abdominal surgery in patients with inflammatory bowel disease.
    Waterman M; Xu W; Dinani A; Steinhart AH; Croitoru K; Nguyen GC; McLeod RS; Greenberg GR; Cohen Z; Silverberg MS
    Gut; 2013 Mar; 62(3):387-94. PubMed ID: 22619367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.